Janux Therapeutics Inc JANX
$17.39 $0.11 (0.64%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
JANX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Janux Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Janux Therapeutics Inc. Stock Analysis JANX
United States Health Care Small Cap Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 109 full-time employees. The company went IPO on 2021-06-11. The company has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Janux Therapeutics Inc (JANX) Chart
Financial Metrics & Statements of Janux Therapeutics Inc (JANX)
FAQ's for Janux Therapeutics Inc (JANX)
- As of August 2026, Janux Therapeutics Inc JANX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Janux Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Janux Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Janux Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Janux Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Janux Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Janux Therapeutics Inc (JANX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
